Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis
JE Martinez-Rodriguez, M Lopez-Botet, E Munteis… - Clinical …, 2011 - Elsevier
CD56bright NK cells, which may play a role in immunoregulation, are expanded in multiple
sclerosis (MS) patients treated with immunomodulatory therapies such as daclizumab and
interferon-beta (IFNβ). Yet, whether this NK cell subset is directly involved in the therapeutic
effect is unknown. As NK receptor (NKR) expression by subsets of NK cells and CD8+ T
lymphocytes is related to MS clinical course, we addressed whether CD56bright NK cells
and NKR in IFNβ-treated MS patients differ according to the clinical response. IFNβ was …
sclerosis (MS) patients treated with immunomodulatory therapies such as daclizumab and
interferon-beta (IFNβ). Yet, whether this NK cell subset is directly involved in the therapeutic
effect is unknown. As NK receptor (NKR) expression by subsets of NK cells and CD8+ T
lymphocytes is related to MS clinical course, we addressed whether CD56bright NK cells
and NKR in IFNβ-treated MS patients differ according to the clinical response. IFNβ was …